Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands

Abstract

Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as anti-BTN1A1 antibodies or anti-BTN1A1 ligand antibodies. Also provided herein are BTN1A1 ligands, such as Galectin-1, Galectin-9, Neuropilin-2, and B- and T-Lymphocyte Attenuator.

1 - 53 . (canceled) 
     
     
         54 . A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a molecule; wherein the molecule comprises an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand; wherein the molecule inhibits binding of BTN1A1 to the BTN1A1 ligand; and wherein the BTN1A1 ligand is selected from the group consisting of Galectin-1 (GAL-1), Galectin-9 (GAL-9), NRP-2 (Nrp-2), and B− and T-Lymphocyte Attenuator (BTLA). 
     
     
         55 . The method of  claim 54 , wherein administration comprises parenteral administration. 
     
     
         56 . The method of  claim 54 , further comprising administering a high-dose radiation therapy to the patient. 
     
     
         57 . The method of  claim 54 , wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, pancreas cancer, ovarian cancer, liver cancer, head and neck cancer, breast cancer, and stomach cancer. 
     
     
         58 . The method of  claim 54 , wherein the cancer is a lung cancer. 
     
     
         59 . The method of  claim 58 , wherein the lung cancer is a non small cell lung cancer (NSCLC). 
     
     
         60 . The method of  claim 59 , wherein the NSCLC is squamous NSCLC. 
     
     
         61 . The method of  claim 58 , wherein the lung cancer is a small cell lung cancer. 
     
     
         62 . The method of  claim 54 , wherein the cancer is an anti-PD-1 therapy or an anti-PD-L1 therapy resistant or refractory cancer. 
     
     
         63 . The method of  claim 62 , wherein the cancer is a breast cancer or a lung cancer. 
     
     
         64 . The method of  claim 63 , wherein the cancer is a mammary carcinoma or a Lewis lung carcinoma. 
     
     
         65 . The method of  claim 54 , wherein the molecule is not STC810 or does not comprise a CDR or VH or VL amino acid sequence of STC810, as described in International Application No. PCT/US16/64436. 
     
     
         66 . The method of  claim 54 , wherein the molecule is an antibody. 
     
     
         67 . The method of  claim 66 , wherein the antibody is a monoclonal antibody. 
     
     
         68 . The method of  claim 66 , wherein the antibody is a human antibody or a humanized antibody. 
     
     
         69 . The method of  claim 66 , wherein the antibody is an IgG, IgM, or IgA. 
     
     
         70 . The method of  claim 66 , wherein the molecule is a Fab′, a F(ab′)2, a F(ab′)3, a monovalent scFv, a bivalent scFv, or a single domain antibody. 
     
     
         71 . The method of  claim 66 , wherein the molecule is recombinantly produced. 
     
     
         72 . The method of  claim 66 , wherein the molecule is contained in a pharmaceutical composition comprising the molecule, and a pharmaceutically acceptable carrier. 
     
     
         73 . The method of  claim 72 , wherein the pharmaceutical composition is formulated for parenteral administration.